|

A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer

RECRUITINGPhase 1Sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia
Actively Recruiting
PhasePhase 1
SponsorNational Medical Research Radiological Centre of the Ministry of Health of Russia
Started2025-02-11
Est. completion2027-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma. The study will assess radiation dose distribution, adverse effects, and preliminary efficacy following selective arterial radioembolization.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed pancreatic adenocarcinoma (T4N0/1M0/1)
* ECOG performance status 0-1, for at least 2 weeks
* Life expectancy ≥12 weeks
* Signed informed consent for participation

Exclusion Criteria:

* ECOG \>2 or Karnofsky score \<60%
* Active gastrointestinal ulcers or recent GI bleeding (\<3 months)
* Active Hepatitis B/C or other significant infectious disease
* Uncontrolled cardiovascular disease (NYHA class III/IV heart failure, recent MI, severe arrhythmias)
* Significant haematological abnormalities (ANC \<1.5×10⁹/L, platelets \<100×10⁹/L, haemoglobin \<8 g/dL)
* Severe hepatic dysfunction (total bilirubin \>1.5×ULN, ALT/AST \>4×ULN without liver metastases)
* Prior solid organ transplant
* Pregnancy or lactation
* Any condition deemed by investigators as unsafe for participation

Conditions2

CancerPancreatic Cancer Non-resectable

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.